BMC Medical Genetics | |
Association between XRCC1 polymorphism 399 G->A and glioma among Caucasians: a systematic review and meta-analysis | |
Michael B Bracken2  Daniel I Jacobs1  | |
[1] Yale School of Public Health, New Haven, CT, USA;Center for Perinatal, Pediatric and Environmental Epidemiology, Yale School of Public Health, New Haven, CT, USA | |
关键词: Meta-analysis; Polymorphisms; XRCC1; Glioma; | |
Others : 1177784 DOI : 10.1186/1471-2350-13-97 |
|
received in 2012-02-29, accepted in 2012-10-22, 发布年份 2012 | |
【 摘 要 】
Background
The x-ray cross complementing group 1 gene (XRCC1) is crucial to proper repair of DNA damage such as single-strand DNA breaks. A non-synonymous polymorphism in XRCC1, 399 G → A, has been shown to reduce effectiveness of such DNA repair and has been associated with the risk of certain cancers. The known risk for glioma from high dose ionizing radiation makes associations between this polymorphism and glioma of particular interest.
Methods
A systematic literature review and meta-analysis was conducted to explore the association between XRCC1 399 G → A and glioma. Subgroup analyses by grade, gender, genotyping method, country in which study was conducted, and study size were conducted when data were available and validity of the results were assessed by influence analyses and exploration of potential publication bias.
Results
Six studies were eligible for meta-analysis including data on 2,362 Caucasian glioma cases and 3,085 Caucasian controls. Pooled analysis yielded a significant association between the variant of interest and risk of glioma (OR = 1.17, 95% CI: 1.05-1.30) which was found to be disproportionately driven by a single study. Exclusion of this study, in an influence analysis, produced no statistically significant evidence of association with glioma (OR = 1.10, 95% CI: 0.98-1.23), and no evidence of publication bias.
Conclusions
This meta-analysis does not suggest a major role of the XRCC1 399 G → A polymorphism in influencing risk of glioma among Caucasians. Future studies should report data separately for glioma subtypes to permit stratified analyses for Grade III and Grade IV glioma and examine other polymorphisms in this gene.
【 授权许可】
2012 Jacobs and Bracken; licensee BioMed Central Ltd.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
20150504024120752.pdf | 335KB | download | |
Figure 2. | 45KB | Image | download |
Figure 1. | 36KB | Image | download |
【 图 表 】
Figure 1.
Figure 2.
【 参考文献 】
- [1]CBTRUS: CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2008. Source. Hinsdale: Central Brain Tumor Registry of the United States; 2010. Accessed at: http://www.cbtrus.org webcite
- [2]Wen PY, Kesari S: Malignant gliomas in adults. N Engl J Med 2008, 359:492-507.
- [3]Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, Il’yasova D, Kruchko C, McCarthy BJ, Rajaraman P, Schwartzbaum JA, Sadetzki S, Schlehofer B, Tihan T, Wiemels JL, Wrensch M, Buffler PA: Brain Tumor Epidemiology Consortium: Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 2008, 113(7):1953-1968.
- [4]Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M: Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2006, 2:494-503.
- [5]Ostrom QT, Barnholtz-Sloan JS: Current state of our knowledge on brain tumor epidemiology. Curr Neurol Neurosci Rep 2011, 11:329-335.
- [6]Wrensch M, Jenkins RB, Chang JS, Yeh RF, Xiao Y, Decker PA, Ballman KV, Berger M, Buckner JC, Chang S, Giannini C, Halder C, Kollmeyer TM, Kosel ML, LaChance DH, McCoy L, O’Neill BP, Patoka J, Pico AR, Prados M, Quesenberry C, Rice T, Rynearson AL, Smirnov I, Tihan T, Wiemels J, Yang P, Wiencke JK: Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet 2009, 41:905-908.
- [7]Sanson M, Hosking FJ, Shete S, Zelenika D, Dobbins SE, Ma Y, Enciso-Mora V, Idbaih A, Delattre JY, Hoang-Xuan K, Marie Y, Boisselier B, Carpentier C, Wang XW, Di Stefano AL, Labusserière M, Gousias K, Schramm J, Boland A, Lechner D, Gut I, Armstrong G, Liu Y, Yu R, Lau C, Di Bernardo MC, Robertston LB, Muir K, Hepworth S, Swerdlow A, et al.: Chromosome 7p11.2 (EGFR) variation influences glioma risk. Hum Mol Genet 2011, 20:2897-2904.
- [8]Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B, Simon M, Marie Y, Boisselier B, Delattre JY, Hoang-Xuan K, El Hallani S, Idbaih A, Zelenika D, Andersson U, Henriksson R, Bergenheim AT, Feychting M, Lönn S, Ahlbom A, Schramm J, Linnebank M, Hemminki K, Kumar R, Hepworth SJ, Price A, Armstrong G, Liu Y, Gu X, Yu R, et al.: Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 2009, 41:899-904.
- [9]Almeida KH, Sobol RW: A unified view of base excision repair: lesion-dependent protein complexes regulated by post-translational modification. DNA Repair (Amst) 2007, 6:695-711.
- [10]Vidal AE, Boiteux S, Hickson ID, Radicella JP: XRCC1 coordinates the initial and late stages of DNA a basic site repair through protein-protein interactions. EMBO J 2001, 20:6530-6539.
- [11]Kubota Y, Nash RA, Klungland A, Schär P, Barnes DE, Lindahl T: Reconstitution of DNA base excision-repair with purified human proteins: interaction between DNA polymerase beta and the XRCC1 protein. EMBO J 1996, 15:6662-6670.
- [12]Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW, Boudreau A, Hardenbol P, Leal SM, Pasternak S, Wheeler DA, Willis TD, Yu F, Yang H, Zeng C, Gao Y, Hu H, Hu W, Li C, Lin W, Liu S, Pan H, Tang X, Wang J, Wang W, Yu J, Zhang B, Zhang Q, International HapMap Consortium, et al.: A second generation human haplotype map of over 3.1 million SNPs. Nature 2007, 449:851-861.
- [13]Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA: XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 1999, 59:2557-2561.
- [14]Duell EJ, Wiencke JK, Cheng TJ, Varkonyi A, Zuo ZF, Ashok TDS, Mark EJ, Wain JC, Christiani DC, Kelsey KT: Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 2000, 21:965-971.
- [15]Kiyohara C, Takayama K, Nakanishi Y: Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis. Lung Cancer 2006, 54:267-283.
- [16]Saadat M, Ansari-Lari M: Polymorphism of XRCC1 (at codon 399) and susceptibility to breast cancer, a meta-analysis of the literatures. Breast Cancer Res Treat 2009, 115:137-144.
- [17]Geng J, Zhang Q, Zhu C, Wang J, Chen L: XRCC1 genetic polymorphism Arg399Gln and prostate cancer risk: a meta-analysis. Urology 2009, 74:648-653.
- [18]Li H, Ha TC, Tai BC: XRCC1 gene polymorphisms and breast cancer risk in different populations: a meta-analysis. Breast 2009, 18:183-191.
- [19]Huang Y, Li L, Yu L: XRCC1 Arg399Gln, Arg194Trp and Arg280His polymorphisms in breast cancer risk: a meta-analysis. Mutagenesis 2009, 24:331-339.
- [20]Wei B, Zhou Y, Xu Z, Ruan J, Zhu M, Jin K, Zhou D, Hu Q, Wang Q, Wang Z, Yan Z: XRCC1 Arg399Gln and Arg194Trp polymorphisms in prostate cancer risk: a meta-analysis. Prostate Cancer Prostatic Dis 2011, 14:225-231.
- [21]Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6:e1000097.
- [22]Liu Y, Scheurer ME, El-Zein R, Cao Y, Do KA, Gilbert M, Aldape KD, Wei Q, Etzel C, Bondy ML: Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev 2009, 18:204-214.
- [23]Thakkinstian A, McElduff P, D’Este C, Duffy D, Attia J: A method for meta-analysis of molecular association studies. Stat Med 2005, 24:1291-1306.
- [24]Higgins JPT, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
- [25]Cengiz SL, Acar H, Inan Z, Yavuz S, Baysefer A: Deoxy-ribonucleic acid repair genes XRCC1 and XPD polymorphisms and brain tumor risk. Neurosciences (Riyadh) 2008, 13:227-232.
- [26]Custódio AC, Almeida LO, Pinto GR, Santos MJ, Almeida JRW, Clara CA, Rey JA, Casartelli C: Analysis of the polymorphisms XRCC1Arg194Trp and XRCC1Arg399Gln in gliomas. Genet Mol Res 2011, 10:1120-1129.
- [27]Felini MJ, Olshan AF, Schroeder JC, North KE, Carozza SE, Kelsey KT, Liu M, Rice T, Wiencke JK, Wrensch MR: DNA repair polymorphisms XRCC1 and MGMT and risk of adult gliomas. Neuroepidemiology 2007, 29:55-58.
- [28]Goode EL, Ulrich CM, Potter JD: Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002, 11:1513-1530.
- [29]Hu Z, Ma H, Chen F, Wei Q, Shen H: XRCC1 polymorphisms and cancer risk: a meta-analysis of 38 case–control studies. Cancer Epidemiol Biomarkers Prev 2005, 14:1810-1818.
- [30]Kiuru A, Lindholm C, Heinävaara S, Ilus T, Jokinen P, Haapasalo H, Salminen T, Christensen HC, Feychting M, Johansen C, Lönn S, Malmer B, Schoemaker MJ, Swerdlow AJ, Auvinen A: XRCC1 and XRCC3 variants and risk of glioma and meningioma. J Neurooncol 2008, 88:135-142.
- [31]McKean-Cowdin R, Barnholtz-Sloan J, Inskip PD, Ruder AM, Butler MA, Rajaraman P, Razavi P, Patoka J, Wiencke JK, Bondy ML, Wrensch M: Associations between polymorphisms in DNA repair genes and glioblastoma. Cancer Epidemiol Biomarkers Prev 2009, 18:1118-1126.
- [32]Rajaraman P, Hutchinson A, Wichner S, Black PM, Fine HA, Loeffler JS, Selker RG, Shapiro WR, Rothman N, Linet MS, Inskip PD: DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol 2010, 12:37-48.
- [33]Wang LE, Bondy ML, Shen H, El-Zein R, Aldape K, Cao Y, Pudavalli V, Levin VA, Yung WK, Wei Q: Polymorphisms of DNA repair genes and risk of glioma. Cancer Res 2004, 64:5560-5563.
- [34]Yosunkaya E, Kucukyuruk B, Onaran I, Gurel CB, Uzan M, Kanigur-Sultuybek G: Glioma risk associates with polymorphisms of DNA repair genes, XRCC1 and PARP1. Br J Neurosurg 2010, 24:561-565.
- [35]Thompson LH, West MG: XRCC1 keeps DNA from getting stranded. Mutat Res 2000, 459:1-18.
- [36]Monaco R, Rosal R, Dolan M, Pincus MR, Brandt-Rauf PW: Conformational effects of a common codon 399 polymorphism on the BRCT1 domain of the XRCC1 protein. Protein J 2007, 26:541-546.
- [37]Vodicka P, Stetina R, Polakova V, Tulupova E, Naccarati A, Vodickova L, Kumar R, Hanova M, Pardini B, Slyskova J, Musak L, De Palma G, Soucek P, Hemminki K: Association of DNA repair polymorphisms with DNA repair functional outcomes in healthy human subjects. Carcinogenesis 2007, 28:657-664.
- [38]Jenkins RB, Wrensch MR, Johnson D, Fridley BL, Decker PA, Xiao Y, Kollmeyer TM, Rynearson AL, Fink S, Rice T, McCoy LS, Halder C, Kosel ML, Giannini C, Tihan T, O’Neill BP, Lachance DH, Yang P, Wiemels J, Wiencke JK: Distinct germ line polymorphisms underlie glioma morphologic heterogeneity. Cancer Genet 2011, 204:13-18.